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Abstract
Context: Medicinal plants encompass a rich source of active compounds that can neutralize snake venoms or toxins. Costus spicatus (Jacq.) Sw. (Costaceae) is used by the Amazonian population to treat inflammation, pain and other pathological manifestations.
Objective: To evaluate the influence of C. spicatus aqueous extract on edema, peritonitis, nociception, coagulation, haemorrhage and indirect haemolytic activity induced by Bothrops atrox venom (BAV).
Materials and methods: Dried and pulverized leaves were extracted with distilled water. Envenoming was induced by administration of B. atrox
snake venom in Swiss Webster mice. The experimental groups consisted of BAV (at the minimum dose to induce measurable biological responses) and C. spicatus extract (CSE, 1.25, 2.5, 5.0, 7.5 and 10 mg/kg/25 ml phosphate-buffered saline) administered individually and in combination (BAVCSE). PBS was used as a control. In vitro assays were also conducted in order to evaluate phospholipase A2 coagulant activities (indirect haemolytic method).
Results: CSE significantly reduced the venom-induced edema and nociception at all concentrations tested and inhibited migration of inflammatory
cells at the three least concentrations (5.0, 7.5 and 10 mg/kg/25 ml PBS). CSE was not effective in inhibiting coagulant, haemorrhagic and indirect haemolytic activities of the venom.
Discussion and conclusion: The data suggest that CSE could exhibit a central mechanism for pain inhibition, and may also inhibit prostaglandin
synthesis. These findings corroborate the traditional administration of C. spicatus decoction to treat inflammatory disorders, including those
caused by B. atrox envenomation.
Keywords: Medicinal plants, snakebites, toxins

Introduction
Bothrops atrox (Viperidae), the common lancehead, is a terrestrial, generally nocturnal and highly adaptable pit viper
found in tropical lowlands and rainforest (Campbell & Lamar 2004). Poisoning by B. atrox, as with other species, triggers local and systemic effects in victims (Borges et al. 1999).
This species is responsible for most snakebites in the Amazon rainforest region, where difficulties in access to healthcare might increase accident severity.
Bothropic envenoming induces prominent local lesions
that are caused by the combined action of venom proteases, haemorrhagic factors, phospholipases A2 (PLA2) and

from the release of endogenous mediators (Rothschild &
Rothschild 1979; Gutiérrez & Lomonte 1989; Trebien & Calixto 1989; Farsky et al. 1997; Carneiro et al. 2002; Laing et
al. 2003; Teixeira et al. 2003). Adequate treatment of snakebite envenoming depends on the ability of antivenoms to reverse systemic signs, such as venom-induced coagulopathy,
haemorrhage, hypotensive shock, among others (Calvete et
al. 2009; Núñez et al. 2009). Animal models and clinical studies have demonstrated that local reactions are not effectively
neutralized by conventional antivenom serum therapy (AvilaAgüero et al. 2001; Lomonte et al. 2009). In severe cases,
local effects of envenoming may lead to permanent tissue
loss, disability or amputation (Gutiérrez 2002). Such adverse
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complications can be controlled by use of anti-inflammatory
remedies concomitant with antivenom to reduce local pain
and inflammation.
Use of medicinal plants has been an elected practice
throughout human history, whose knowledge, gathered
through the experience of many generations, represents
millennia of popular wisdom, since the times when the only
available medicinal resources were obtained from the vegetal kingdom (Calixto et al. 2000). Medicinal plants still play
a key role in world health as they are a rich source of many
natural inhibitors and pharmacologically active compounds.
Many of these substances structurally resemble biological
compounds, and this similarity is the basis of their physiological action (Havsteen 1983). Some medicinal plants are used
in the Amazon and elsewhere against snakebites or as antiinflammatory agents, and these plants may prove valuable
adjuvants to antivenom therapies (da Silva et al. 2005; Soares
et al. 2005; Bittencourt et al. 2014). Hence, it is crucial to undertake an in-depth scientific investigation on the pharmacological and toxicological actions of these plants.
Costus spicatus Swartz (Costaceae), commonly called
‘cana-do-brejo’, ‘canafístula’ or ‘canarana’ in Brazil, is a medicinal plant found in wet coastal forests (Silva 2002; da Silva
& Parente 2003). Ethnopharmacological surveys have established that C. spicatus leaf and stem decoctions as well
as aqueous or alcoholic infusions are commonly used for
the treatment of renal calculi, cutaneous ulcers, infections,
inflammation, urethritis, gonorrhea and leucorrhoea (Carriconde et al. 1996; Araújo Viel et al. 1999; da Silva et al.
2000; Silva 2002). Studies have reported the isolation and
chemical characterization of three neutral polysaccharides
with anti-inflammatory and immunomodulatory activities
(da Silva & Parente 2003). Other work has demonstrated
that methanol extract obtained from the leaves possessed
analgesic and anti-inflammatory properties (Quintans Júnior
et al. 2010). Owing to the presumed anti-inflammatory potential of C. spicatus aqueous extract, we evaluated its ability to reduce edema, peritonitis, nociception, coagulation,
haemorrhage and indirect haemolytic activity induced by
B. atrox venom (BAV).
Materials and methods
Venom
BAV pool was obtained from four adult specimens captured
at Laranjal do Jari, Amapa State, Brazil (0° 38’ 12.42” S, 52°
30’ 15.87” O). The sampling location was marked by a global
position measuring (GPS Garmin – modelo nüvi 40). Venom
was collected after anesthetizing the snakes with carbon

dioxide gas. The venom samples were lyophilized and kept
at –20 °C in the freezer until further use. The venom was diluted in phosphate-buffered saline (PBS) immediately prior
to its use.
Plant material
Costus spicatus leaves were collected from Macapá in Amapaá
State, Brazil, in the month of February 2012. The sampling location (00° 2’41.821” S, 51° 5’57.2530” W) was deduced by a
global position measuring (GPS Garmin Nüvi 40). The plant
was identified by Prof. Wegliane Campelo da Silva Aparício, a
taxonomist at the Department of Biology, Federal University
of Amapá, Macapa, AP, Brazil. A voucher specimen (N° 460)
was deposited at the Herbarium of the Federal University of
Amapá for future reference.
Preparation of plant extract
Dry and pulverized leaves were extracted with distilled water for 24 h at room temperature. Insoluble material was removed by filtration. The aqueous extract (CSE) was lyophilized and kept at –20 °C in a freezer until further use. Prior
to use, the lyophilized extracts were weighed and dissolved
in PBS.
Animals
Animal care was performed in accordance with the guidelines
of the Brazilian College for Animal Experimentation. Male
Swiss Webster mice weighing 20–25 g were used for the experiments and were randomly divided into groups of five animals. The mice were kept in plastic cages with access to water
and food ad libitum and were maintained under controlled
temperature (18–20 °C) on a 12 h light/dark cycle.
Groups and experimental protocols
The experimental groups were BAV alone, C. spicatus extract
alone (CSE), BAV+CSE in various concentrations (BAVCSE) or
PBS alone. The venom doses used were selected from previous dose-response experiments. This initial study evaluated
different dosages on the ability to induce measurable biological responses. The appropriate doses are specified in each
bioassay description below.
Paw edema induction
The minimum dose was defined as the lowest venom dose
required for the formation of 30% paw edema (Rocha &
Furtado 2007). This minimum dose was evaluated as 0.20
mg/kg by subplantar injection of venom, in the right footpad
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of mice. Inhibition studies were performed with CSE at several concentrations (1.25; 2.5; 5.0; 7.5 and 10 mg CSE/kg). CSE
and venom diluted in 50 ml PBS were injected together. Control animals received PBS (50 ml), venom (0.20 mg/kg/50 ml
PBS) or CSE only (10 mg/kg/50 ml PBS). The progression of
edema was evaluated with a low-pressure pachymeter (Mitutoyo America Corporation, Kanagawa, Japan) 0, 0.5, 1, 2, 3
and 4 h after injection and was expressed in mm of directly
induced edema.
Formalin test
The method used was based on the protocol previously described by Hunskaar and Hole (1987) with modifications recommended by Soares et al. (2009) and De Sousa et al. (2012).
As a further modification, formalin used for pain induction
was substituted by BAV at 0.20 mg/kg. Symptoms of pain
such as intense licking and biting of the paw was recorded
in two phases. The first period (first phase) was recorded between 0 and 5 min and the second period (second phase)
between 20 and 30 min after the injection. The time (in seconds) spent licking and biting the injected paw was taken as
an indicator of pain intensity. The test was performed at ambient temperature (22–26 °C) and care was taken to exclude
environmental disturbances (high temperature, noise and excessive movement) that might influence animal behavior. The
animals were examined by the same observer who was responsible for all tests. Due to the number of animals, tests
were performed during two consecutive days. CSE nociception inhibition was evaluated at five doses (1.25; 2.5; 5.0; 7.5
and 10mg/kg). Accordingly, CSE and BAV (0.20 mg/kg) were
diluted in PBS (50 μl) and each preparation was injected subcutaneously into the right hind paw of five mice. Control animals received PBS (50 μl), venom (0.20 mg/kg/50 μl PBS) or
CSE only (10 mg/kg/50 μl PBS). Mice were then placed under glass funnel individually with mirrors around them to facilitate observation.
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with a plastic Pasteur pipette by abdominal laparoscopy. To
facilitate the collection, all the animals received an injection
of 2.0 ml of heparinized PBS (1/1000 ml de PBS), and their
abdomens were massaged to recover all leukocytes present.
The peritoneal wash samples were diluted in Türk’s solution
(1:20), and the cells were counted in a Neubauer chamber.
The results were expressed as the total number of cells per
peritoneal cavity.
Coagulant activity
The minimum coagulant dose, defined as the amount of
venom that causes clotting of 200 ml human plasma in 60 s
was 20 μg (Theakston & Reid 1983). For the inhibition tests,
several doses of CSE (26; 52; 104; 208; 416 μg) and BAV (20
μg) diluted in PBS (50 μl) were added immediately to citrated
human plasma (200 μl) maintained at 37 °C. Clotting times
were recorded. In control assays, PBS (50 μl), BAV (20 μg/50
μl PBS) and CSE (416 mg/50 μl PBS) were added to citrated
human plasma.
Haemorrhagic activity
Haemorrhage was induced by intradermal injections performed on the back of mice. After 2 h, the animals were euthanized in a CO2 chamber. The skin near the injection site
was removed and haemorrhagic halo formed was measured
in millimeters (mm) according to the method of Kondo et al.
(1960). The diameters of the haemorrhage spot where the average of the longest diameter of the spot and the diameter
perpendicular to the first measurement. The dose of venom
inducing a 10mm haemorrhagic spot was 0.20 mg/kg. In the
inhibition assays, mixtures of BAV (0.20 mg/kg) and CSE at
five concentrations (1.25; 2.5; 5.0; 7.5 and 10 mg/kg) were
mixed in PBS (50 μl) and were injected intradermally. Control
animals received PBS (50 μl), venom (0.20 mg/kg/50 μl PBS)
or CSE (10 mg/kg/50 μl PBS).

Peritonitis induced by B. atrox venom

Indirect haemolytic method

Peritonitis assays were performed as previously described
by Souza and Ferreira (1985) and Souza (2006). The optimal
venom dose required to induce cellular migration without
causing significant local haemorrhage was 0.20 mg/kg. In the
inhibition assays, mixtures of BAV (0.20 mg/kg) and CSE (1.25;
2.5; 5.0; 7.5 and 10 mg/kg) in PBS (50 μl) were administered
intraperitoneally. Control animals received PBS (50 μl), venom
(0.20 mg/ kg/50 μl PBS) or CSE (10 mg/kg/50 μl PBS) by intraperitoneal route. After 4 h, the animals were euthanized in
a CO2 chamber and the peritoneal exudates were collected

PLA2 activity was determined by an indirect haemolytic
method using agarose, Tris (20 mm), CaCl2 and egg yolk gels
as substrate (Gutiérrez et al. 1988). The amount of BAV that
produced a 10mm halo was 20 mg. Mixtures of BAV (20 μg)
and CSE (50 μl) at five concentrations (26; 52; 104; 208 or
416 mg/25 μl PBS) were applied at the center of the dish. After incubation at 37 °C for 12 h, the PLA2 activity was evaluated measuring the diameter of the translucent halo formed.
PBS (50 μl), venom (20 mg/50 μl PBS) or CSE (416 mg/50 μl
PBS) were used as controls. Measurements were recorded in
triplicates.
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Statistical analysis
The results are presented as the mean ± SEM. Differences
among groups were analyzed by one-way analysis of variance (ANOVA) followed by Tukey–Kramer test. The differences were considered to be significant when the associated
probability of a null hypothesis (p values) were less than 5%
(p < 0.05).
Results
Application of venom-induced edema and the size of the
edema measuring the effect of CSE at time 0; 0.5; 1; 2; 3 and
4 h after injection is reported in Table 1. CSE significantly reduced edema at all concentrations tested (1.25; 2.5; 5.0; 7.5
and 10 mg/kg/25 μl PBS) when compared with BAV alone.
In the nociception assay, the time spent licking and biting
over fixed periods of time after subcutaneous injection of
0.20 mg/kg BAV into the right hind paw was recorded as an
indicator of pain. In this assay, CSE demonstrated the analgesic effect on the first (0–5 min) and second phases (20–
30 min) of BAV-induced pain (Figure 1). These phases correspond to neurogenic and inflammatory pain, respectively.
In the first phase (Figure 1A), CSE significantly reduced neurogenic pain at all concentrations when compared with the
BAV group. The analgesic effect was stronger at higher concentration of CSE. In the second phase (Figure 1B), all doses
of CSE significantly neutralized inflammatory pain compared
with the animals treated with BAV alone. However, in this
phase, lower concentrations of CSE exhibited slightly higher
analgesic potential.
The influx of leukocytes was analyzed by counting the
cells in the peritoneal wash (Figure 2). CSE significantly

decreased the number of leukocytes at the three lowest concentrations, which indicated an effect of CSE on the migration
of inflammatory cells induced by venom administration. In vitro studies carried out with human plasma demonstrated that
CSE concentrations used in the present study did not inhibit
venom coagulant activity (Figure 3). CSE effect on haemorrhagic activity induced by BAV was also tested. As observed
in Figure 4, CSE did not significantly inhibit BAV-induced
haemorrhage. Lastly, it was also demonstrated that CSE did
not inhibit the PLA2 activity of BAV, as shown in Figure 5.
Discussion
The main clinical effects of Bothrops envenoming are local tissue damage (myonecrosis, haemorrhage and edema),
life-threatening bleeding originating from blood coagulation disorders and shock (Gutiérrez 1995; Warrell 2004). In
the present study, BAV was used to induce edema, peritonitis, nociception, coagulation, haemorrhage and indirect haemolytic activity, and we evaluated whether or not the aqueous extract obtained from the leaves of C. spicatus Swartz
could quench the effects of the venom. Venom toxicity is due
to its proteins content. Those are mainly metalloproteinases,
lectins, serino-proteinases, bradykinin-potentiating peptides
and PLA2 (Guércio et al. 2006; Neiva et al. 2009).
Quintans Júnior et al. (2010) evaluated the antinociceptive and anti-inflammatory effects of the methanol extract
obtained from the leaves of C. spicatus Swartz (MECs) on
acetic acid-induced writhing, formalin, hotplate and carrageenan-induced edema tests in rodents. Our studies in mice
showed that BAV-induced paw edema immediately after administration and that the edema gradually decreased >4 h.
This envenomation kinetics corroborates those from previous

Table 1. Effect of CSE on the edema induced by B. atrox venom.
Entry

Treatment

0h

0.5 h

1h

2h

3h

4h

1
2
3
4
5
6
7
8

PBS
BAV
CSE
BAVCSE 1:6
BAVCSE 1:12
BAVCSE 1:25
BAVCSE 1:37
BAVCSE 1:50

1.8 ± 0.01
1.88 ± 0.02
1.91 ± 0.01
1.94 ± 0.01
1.94 ± 0.01
1.90 ± 0.01
1.88 ± 0.02
1.92 ± 0.01

2.1 ± 0.01
2.94 ± 0.02
2.35 ± 0.01
2.97 ± 0.001*
2.98 ± 0.03*
2.97 ± 0.01*
2.95 ± 0.01*
2.97 ± 0.01*

2.0 ± 0.01
2.59 ± 0.04
2.06 ± 0.02
2.37 ± 0.07**
2.33 ± 0.02***
2.39 ± 0.02*
2.37 ± 0.02**
2.44 ± 0.01*

1.9 ± 0.01
2.44 ± 0.03
1.97 ± 0.02
2.32 ± 0.07*
2.23 ± 0.03**
2.28 ± 0.01*
2.26 ± 0.03*
2.37 ± 0.01*

1.9 ± 0.01
2.38 ± 0.04
1.97 ± 0.02
2.15 ± 0.04***
2.18 ± 0.01**
2.24 ± 0.01*
2.18 ± 0.03***
2.30 ± 0.01*

1.9 ± 0.01
2.38 ± 0.04
1.97 ± 0.02
2.09 ± 0.03***
2.14 ± 0.0***
2.17 ± 0.01***
2.11 ± 0.02***
2.21 ± 0.01**

4. BAVCSE 1:6 (BAV + 1.25 mg CSE/kg/25 μl PBS); 5. BAVCSE 1:12 (BAV + 2.5 mg CSE/kg/25 μl PBS); 6. BAVCSE 1:25 (BAV + 5.0 mg CSE/kg/25 μl
PBS); 7. BAVCSE 1:37 (BAV + 7.5 mg CSE/kg/25 μl PBS); 8. BAVCSE 1:50 (BAV + 10mg CSE/kg/25 μl PBS). The results are presented as the mean ±
SEM on three animals. CSEtreated groups and BAV group were compared by one-way analysis of variance (ANOVA), followed by Tukey–Kramer
test. Differences with an associated probability (p values) of less than 5% were considered significant.
* p < 0.05
** p < 0.01
*** p < 0.001
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Figure 1. Effect of CSE on the first (panel A) and the second phase (panel B) of BAV-induced nociception in mice. BAVCSE 1:6: BAV + 1.25 mg CSE/
kg/50 μl PBS; BAVCSE 1:12: BAV + 2.5 mg CSE/kg/50 μl PBS; BAVCSE 1:25: BAV + 5.0 mg CSE/kg/50 μl PBS; BAVCSE 1:37: BAV + 7.5 mg CSE/kg/50
μl PBS; BAVCSE 1:50: BAV + 10mg CSE/kg/50 μl PBS. The results are presented as mean ± SEM for five animals. Differences between BAVCSE groups
and BAV group were analyzed by one-way analysis of variance (ANOVA), followed by the Tukey–Kramer test. Differences with an associated probability (p values) of less than 5% (p < 0.05) were considered significant.
*p < 0.05; **p < 0.01; ***p < 0.001.

Figure 2. Peritonitis induced by B. atrox venom and treated with CSE.
BAVCSE 1:6: BAV + 1.25 mg CSE/kg/50 μl PBS; BAVCSE 1:12: BAV + 2.5
mg CSE/kg/50 μl PBS; BAVCSE 1:25: BAV + 5.0 mg CSE/kg/50 μl PBS;
BAVCSE 1:37: BAV + 7.5 mg CSE/kg/50 μl PBS; BAVCSE 1:50: BAV + 10mg
CSE/kg/50 μl PBS. The results are presented as the mean ± SEM for five
animals. Differences between BAVCSE groups and BAV group were analyzed by one-way analysis of variance (ANOVA), followed by Tukey–
Kramer test. Differences with an associated probability (p values) of less
than 5% (p < 0.05) were considered significant. *p < 0.05;
**p < 0.01.

Figure 3. CSE effect on B. atrox venom coagulant activity. BAV: 20 mg/50
μl PBS. BAVCSE 1:1: BAV + 26 mg CSE/50 μl PBS; BAVCSE 1:2: BAV + 52
mg CSE/50 μl PBS; BAVCSE 1:5: BAV + 104 mg CSE/ 50 μl PBS; BAVCSE
1:10: BAV + 208 mg CSE/50 μl PBS; BAVCSE 1:20: BAV + 416 mg CSE/50
μl PBS. Each experiment was carried out in triplicate. Differences between
BAVCSE groups and BAV group were analyzed by one-way analysis of
variance (ANOVA), followed by Tukey–Kramer test. Results did not vary
significantly as compared with BAV (p > 0.05).

studies that demonstrated the ability of Bothrops venom to
induce edema through the action of venom constituents on
vascular endothelial cells and inflammatory mediators (Barbosa et al. 2008). Interestingly, we found that CSE diminished
the edematogenic effect of BAV at all tested doses and that
the effect lasted for 4 h. CSE also produced a significant inhibitory effect on the migration of inflammatory cells after
the venom had been injected. The effect was stronger at

the lowest concentrations tested. Many studies suggest that
presence of glucan polysaccharides may act on the reticuloendothelial system, through phagocytosis stimulation, and
can also induce vascular reactions, affecting the capillary permeability of the vessels (Whistler et al. 1976). Interestingly,
glucans have been isolated from C. spicatus by da Silva and
Parente (2003). Quintans Júnior et al. (2010) reported that
the first phase of the edematous response was significantly
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Figure 4. Effect of CSE on haemorrhage induced by B. atrox venom.
BAV: 0.40 mg/50 μl PBS. BAVCSE 1:16: BAV + 3.2 mg CSE/kg/50 μl PBS;
BAVCSE 1:32: BAV + 6.4 mg CSE/kg/50 μl PBS; BAVCSE 1:64: BAV + 12.8
mg CSE/kg/50 μl PBS; BAVCSE 1:96: BAV + 19.2 mg CSE/kg/50 μl PBS;
BAVCSE 1:128: BAV + 25.6 mg CSE/kg/50 μl PBS. The results are presented as the mean ± SEM of five animals. Differences between BAVCSE
groups and BAV group were analyzed by one-way analysis of variance
(ANOVA), followed by Tukey–Kramer test. Results in BAVCSE experiments
did not vary significantly as compared with BAV (p > 0.05).

Figure 5. Effects of CSE on phospholipase A2 activity of B. atrox venom.
BAV: 20 μg/50 μl PBS. BAVCSE 1:1: BAV + 26 μg CSE/50 μl PBS; BAVCSE
1:2: BAV + 52 μg CSE/50 μl PBS; BAVCSE 1:5: BAV + 104 μg CSE/50 ml
PBS; BAVCSE 1:10: BAV + 208 μg BGE/50 μl PBS; BAVCSE 1:20: BAV +
416 μg CSE/50 μl PBS. The results are presented as the mean ± SEM of
five animals. Differences between BAVCSE groups and BAV group were
analyzed by one-way analysis of variance (ANOVA), followed by Tukey–
Kramer test. Results in BAVCSE experiments did not vary significantly as
compared with BAV (p > 0.05).

lower in the presence of C. spicatus methanol extract (MECs)
in rats, suggesting an inhibitory effect on the release of histamine and/or serotonin. MECs also inhibited significantly the
second and third phases of the edema, suggesting inhibition
of 5-lipoxygenase and/or cyclooxygenase, the enzymes involved in the formation of prostaglandins and leukotrienes.
The first experimental evidence that Bothrops venoms
induce hyperalgesia (pain hypersensitivity) was provided by
Teixeira et al. (1994). In this study, the authors induced a
long-lasting hyperalgesia mediated mainly by prostaglandin, leukotriens and PAF using B. jararaca venom. Chacur et
al. (2001) demonstrated that bradykin is involved in hyperalgesia induced by B. jararaca venom, which peaked 1 h after venom injection.
The pain phenomenon takes its origin from peripheral
sensory nerve fibres through activation of nociceptors that
relay noxious stimuli from the periphery to the central nervous system (Tortora & Grabowski 2002; Cummins et al.
2007). The results of present study showed that BAV produced a significant nociceptive effect both at 0–5 min and
20–30 min. The early phase may be due to direct effects on
nociceptors, demonstrating that BAV causes an immediate sensation of pain and an increased responsiveness of
neurons. However, more studies are needed to further investigate components and mechanism involved in the nociceptive action of the snake venoms. CSE exhibited antinociceptive activity in the first phase, probably by central action

mechanism. Reports show that flavonoid-rich plant extracts
can exhibit antinociceptive properties due to possible interactions of the flavonoids with the opioid system (Ghannadi et
al. 2005; Maleki-Dizaji et al. 2007; Quintans Júnior et al. 2010).
In the late phase, BAV nociceptive effect can be due to an
inflammatory response. Inflammation induced by Bothrops
venom is characterized by a complex network of chemical
mediators and the cellular components responsible for such
effects. Besides the role of stored and newly generated inflammatory mediators, enzymes present in the venom, mainly
PLA2 and metalloproteinases, appear to play a role in inflammation and hyperalgesia induced by B. asper venom (Teixeira
et al. 2009). Our experiments showed that CSE exhibited antinociceptive activity also in the second phase as well. da Silva
et al. (2000) isolated flavonol diglycosides tamarixetin 3-Oneohesperidoside, kaempferide 3-O-neohesperidoside and
the known quercetin 3-O-neohesperidoside together with six
known flavonoids from C. spicatus leaves. Tamarixetin 3-Oneohesperidoside and kaempferide 3-O-neohesperidoside
showed slight inhibitory activity on nitric oxide production by
activated macrophages. This information suggests that CES
may act on inflammatory disorders, probably by a peripheral
mechanism. These findings corroborate the traditional analgesic and anti-inflammatory indication of the leaf infusion.
On the other hand, our work demonstrated that CSE was not
effective to inhibit coagulant, haemorrhagic and indirect haemolytic activities induced by BAV.

Pharmacological Activity of C. spicatus in B. atrox Envenomation

Conclusion
This study demonstrates that C. spicatus leaf aqueous extract
has a significant inhibitory effect on edema and migration
of inflammatory cells, mainly at the lowest concentrations
tested. Moreover, CSE significantly reduced BAV-induced nociception in the first and second phases. CSE presumably
acts through a central inhibitory mechanism while inhibiting prostaglandin synthesis as well. The present study contributes to validate the traditional use of C. spicatus leaf infusion against inflammatory disorders including those caused
by snake envenomation and accentuates the importance of
popular knowledge in the search for alternative treatments
to snakebite.
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